Momelotinib in VEXAS Syndrome
NCT07098936
Bone Marrow Diseases, Hematologic Diseases
Angers, France
View Trial DetailsNCT Number: NCT06004349
This is an exploratory natural history protocol that will enroll patients with known genetic diseases, such as VEXAS syndrome, or as yet undiagnosed disorders of inflammation with the goal of improving our understanding of disease processes. Blood, saliva, hair, nail, or buccal samples may be collected for genetic analysis, blood samples will be obtained for immunologic and other functional studies, and a small number of subjects may undergo skin biopsy.
Interested in participating?
Request Info1 month and older
All sexes
Observational
NYC H+H/Bellevue, New York, United States
This is a single-site protocol designed to test the hypothesis that genetic factors contribute to susceptibility to human disorders of inflammation, and the hypothesis that identifying such genetic susceptibility factors will contribute to our understanding of the immunologic mechanisms of these diseases.
There are 3 main objectives:
Primary Objective: To discover the genetic basis of human disorders of inflammation or autoinflammatory diseases.
Secondary Objective: To enumerate immunologic features and genotype-phenotype associations in specific inflammatory diseases, such as VEXAS syndrome.
Tertiary/Exploratory Objective: To describe the clinical features of poorly characterized or newly defined disorders of inflammation, such as VEXAS syndrome, through the retrospective chart review of standard medical practice follow up
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
In order to be eligible to participate in this study as a subject with known or suspected autoinflammatory disease, an individual must meet all of the following criteria:
In order to be eligible to participate in this study as a family member of a subject with known or suspected autoinflammatory disease, an individual must meet all of the following criteria:
In order to be eligible to participate in this study as a healthy volunteer, an individual must meet all of the following criteria:
Exclusion criteria
For any of the three categories of subjects, an individual will be excluded from participation in this study for the following reasons:
Probands: an individual will not be enrolled as a proband if the study team has a low suspicion of having an autoinflammatory disease or a genetic cause for an autoinflammatory disease.
Family Members: an individual will not be enrolled as a family member if the study team believes they may have an autoinflammatory disease, in which case, they will be enrolled as a proband.
Healthy controls: an individual will not be enrolled as a healthy control if they have an autoinflammatory disease, or any condition that may mimic an autoinflammatory disease, such as hematologic malignancy, rheumatologic disease.
Time frame: Study End (Up to Year 5)
Time frame: Study End (Up to Year 5)
Time frame: Study End (Up to Year 5)
Time frame: Study End (Up to Year 5)
Contact information is provided by the study sponsor or research team.
David Beck, MD, PhD
CONTACT
Mei-Kay Wong, MS, MPH, CGC, CPH
CONTACT
NYU Langone Health
Other
Natural History and Genetics of VEXAS Syndrome and Related Autoinflammatory Syndromes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07098936
Bone Marrow Diseases, Hematologic Diseases
Angers, France
View Trial DetailsNCT00372177
Arthritis, Arthritis, Rheumatoid
Leipzig, Saxony, Germany
View Trial DetailsNCT00977977
Autoimmune Disease, Autoimmune Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT02504879
Bone Diseases, Bone Diseases, Developmental
Bethesda, Maryland, United States
View Trial Details